• Mirum Pharmaceuticals will present rare liver disease data at AASLD’s The Liver Meeting, November 5-9, 2026, in Denver.
• Late-breaking Phase 3 AZURE-1 results will highlight brelovitug monotherapy’s efficacy and safety in chronic hepatitis D.
• Longer-term brelovitug data show deepening virologic and biochemical responses with continued treatment, including in patients with cirrhosis.
• Phase 2b VISTAS analyses show volixibat improved itching in primary sclerosing cholangitis patients without worsening inflammatory bowel disease activity.
• New clinical and real-world evidence will examine Livmarli treatment outcomes in Alagille syndrome and progressive familial intrahepatic cholestasis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611020802BIZWIRE_USPR_____20261102_BW107769) on November 02, 2026, and is solely responsible for the information contained therein.